A. Douglas KinghornProgram for Collaborative Research in the Pharmaceutical Sciences and Department of MedicinalChemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 SouthWood Street, Chicago, IL 60612, U.S.ATel.: (312) 996-0914, Fax: (312) 996-7107, E-mail: kinghorn@uic.eduThere is considerable interest in the screening of plant and other natural product extracts in moderndrug discovery programs, since structurally novel chemotypes with potent and selective biological ac-tivity may be obtained [1-4]. A consideration of biological activity in addition to the isolation andstructure elucidation stages in a phytochemical investigation may add a great deal to the overall scien-tific significance of the work. Phytochemists may gain considerable information by using panels ofsimple bioassays and/or more specialized in vitro bioassays to follow each step of a purification proce-dure [3]. In the following paragraphs, recent examples of bioactive compounds obtained in the author’slaboratory in projects directed towards the search for novel anticancer agents and cancer chemopre-ventives from higher plants will be presented.In the United States in 1999, it is estimated that over 1.2 million persons will be diagnosed with in-vasive forms of cancer, and over 1,500 people will die as a result of cancer each day [5]. Among manyrecent advances in cancer chemotherapy, plant natural products have played an important role in con-tributing to the arsenal of the approximately 60 cancer chemotherapeutic drugs on the market. For in-stance, in the United States, there are now four structural classes of plant anticancer agents available,constituted by the Catharanthus (Vinca) alkaloids (vinblastine, vincristine, vinorelbine), the epipodo-phyllotoxins (etoposide, etoposide phosphate, teniposide), the taxanes (paclitaxel and docetaxel), andthe camptothecin derivatives (irinotecan and topotecan) [6]. Several other plant-derived compoundsare currently in preclinical and clinical trials [6,7].As part of a National Cooperative Natural Products Drug Discovery Group (NCNPDDG) researchproject funded by the United States National Cancer Institute (1995-2000), our collaborative team atthe College of Pharmacy, University of Illinois at Chicago (Chicago, Illinois), and Research TriangleInstitute (Research Triangle Park, North Carolina), and Bristol-Myers Squibb (Princeton, New Jersey)is evaluating about 400 plant samples per year, with the aim of discovering and evaluating novel plant-derived anticancer agents. During the funding period 1990-1995, the industrial partner was GlaxoWellcome Medicines Research Centre (Sevenage, U.K.), and past progress made in the project hasbeen reviewed [8]. Since 1995, the primary plant samples have been collected in the Dominican Re-public, Peru, and Indonesia. Plant recollections have taken place mainly in Thailand and Zimbabwe in